Revvity Beats on Q3 Growth, Guides FY26 Adjusted EPS to $5.40-$5.45
RVTY sits 94% above its 52-week low of $81.22.
Summary
Revvity reported Q3 2026 revenue of $729M versus $699M a year ago, with adjusted EPS of $1.38 versus $1.18, net income of $62.3M and continuing operations EPS of 56c. On a pro forma basis excluding the China IDX divestiture, adjusted EPS was $1.37 versus $1.13 and pro forma revenue rose to $710M from $660M. Life Sciences led with pro forma organic growth of 9%, while Diagnostics grew 5% organically. Management called the quarter 'meaningfully ahead of our expectations' and pointed to improving end markets. Full-year 2026 pro forma guidance calls for revenue of approximately $2.86B, organic growth of approximately 5%, and adjusted EPS of $5.40-$5.45. The company hosts an Investor Day on November 13.
At the time of this announcement, RVTY was trading at $157.77 on NYSE in the Life Sciences sector, with a market capitalization of approximately $16.9B. The 52-week trading range was $81.22 to $169.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.